Signaling pathways of cell proliferation are involved in the differential effect of erythropoietin and its carbamylated derivative

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 8, 2013, Pages 1960-1968

  Chamorro, María Eugenia ^a,b   Wenker, Shirley Denise ^a,b   Vota, Daiana Marina ^a,b   Vittori, Daniela Cecilia ^a,b   Nesse, Alcira Beatriz ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Pabellón II ^*  (Argentina)

Author keywords

Carbamylated erythropoietin; Cell cycle; Cell proliferation; Erythropoietin; FOXO3a; P27kip1

Indexed keywords

CARBAMYLATED DERIVATIVE OF ERYTHROPOIETIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ERYTHROPOIETIN; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ERYTHROID CELLS; ERYTHROPOIESIS; ERYTHROPOIETIN; FORKHEAD TRANSCRIPTION FACTORS; G1 PHASE; HUMANS; NEURONS; PHOSPHORYLATION; RECEPTORS, ERYTHROPOIETIN; S PHASE; SIGNAL TRANSDUCTION;

EID: 84877809493     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.04.006     Document Type: Article

References (35)

1. Sirén A.-L., Fratelli M., Brines M., Goemans C., Casagrande S., Lewczuk P., Keenan S., Gleiter C., Pasquali C., Capobianco A., Mennini T., Heumann R., Cerami A., Ehrereich H., Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:4044-4049.
2. Celik M., Gokmen N., Erbayraktar S., Akhisaroglu M., Konakc S., Ulukus C., Genc S., Genc K., Sagiroglu E., Cerami A., Brines M. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:2258-2263.
3. Rui T., Feng Q., Lei M., Peng T., Zhang J., Xu M., Abel E.D., Xenocostas A., Kvietys P.R. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc. Res. 2004, 65:719-727.
4. Noguchi C.T., Asavaritikrai P., Teng R., Jia Y. Role of erythropoietin in the brain. Clin. Rev. Oncol. Hematol. 2007, 64:159-171.
5. Leist M., Ghezzi P., Grasso G., Bianchi R., Villa P., Fratelli M., Savino C., Bianchi M., Nielsen J., Gerwien J., Kallunki P., Larsen A.K., Helboe L., Chistensen S., Pedersen L.O., Nielsen M., Torup L., Sager T., Sfacteria A., Erbayraktar S., Erbayraktar Z., Gokmen N., Yilmaz O., Cerami-Hand C., Xie Q., Coleman T., Cerami A., Brines M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004, 305:239-242.
6. Brines M., Grasso G., Fiordaliso F., Sfacteria A., Ghezzi P., Fratelli M., Latini R., Xie Q.W., Smart J., Su-Rick C.J., Pobre E., Diaz D., Gomez D., Hand C., Coleman T., Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:14907-14912.
7. Coleman T., Westenfelder C., Tögel F., Yang Y., Hu Z., Swenson L.A., Leuvenink H.G., Ploeg R.J., d'Uscio L.V., Katusic Z.S., Ghezzi P., Zanetti A., Kaushansky K., Fox N.E., Cerami A., Brines M. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5965-5970.
8. Fantacci M., Bianciardi P., Caretti A., Coleman T.R., Cerami A., Brines M., Samaja M. Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17531-17534.
9. Brines M., Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J. Intern. Med. 2008, 264:405-432.
10. Um M., Gross A.W., Lodish H.F. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell. Signal. 2006, 19:634-645.
11. Habeeb A.F. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal. Biochem. 1966, 14:328-336.
12. Garbossa G., Gutnisky A., Nesse A. The inhibitory action of aluminum on mouse bone marrow cell growth: evidence for an erythropoietin- and transferrin-mediated mechanism. Miner. Electrolyte Metab. 1994, 20:141-146.
13. Vittori D., Nesse A., Pérez G., Garbossa G. Morphologic and functional alterations of morphologic and functional alterations of erythroid cells induced by long-term ingestion of aluminium. J. Inorg. Biochem. 1999, 76:113-120.
14. Vittori D., Pregi N., Pérez G., Garbossa G., Nesse A. The distinct erythropoietin functions that promote cell survival and proliferation are affected by aluminum exposure through mechanisms involving erythropoietin receptor. Biochim. Biophys. Acta 2005, 1743:29-36.
15. Callero M., Vota D.M., Chamorro M.E., Wenker S.D., Vittori D.C., Nesse A.B. Calcium as a mediator between erythropoietin and protein tyrosine phosphatase 1B. Arch. Biochem. Biophys. 2010, 505:242-249.
16. Wenker S.D., Chamorro M.E., Vota D.M., Callero M.A., Vittori D.C., Nesse A.B. Differential antiapoptotic effect of erythropoietin on undifferentiated and retinoic acid-differentiated SH-SY5Y cells. J. Cell. Biochem. 2010, 110:151-161.
17. Pregi N., Vittori D., Pérez G., Pérez Leirós C., Nesse A. Effect of erythropoietin on staurosporine-induced apoptosis and differentiation of SH-SY5Y neuroblastoma cells. Biochim. Biophys. Acta 2006, 1763:238-246.
18. Laemmli U.K. Cleavage of structural protein during the assembly for the head of bacteriphage T4. Nature 1970, 227:680-685.
19. kip1. Cell Cycle 2008, 7:257-266.
20. Koury M.J., Sawyer S.T., Brandt S.J. New insights into erythropoiesis. Curr. Opin. Hematol. 2002, 9:93-100.
21. Sautina L., Sautin Y., Beem E., Zhou Z., Schuler A., Brennan J., Zharikov S.I., Diao Y., Bungert J., Segal M.S. Induction of nitric oxide by erythropoietin is mediated by the β common receptor and requires interaction with VEGF receptor 2. Blood 2010, 115:896-905.
22. Su K.H., Shyue S.K., Kou Y.R., Ching L.C., Chiang A.N., Yu Y.B., Chen C.Y., Pan C.C., Lee T.S. β common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase. J. Cell. Physiol. 2011, 226:3330-3339.
23. Masuda S., Nagao M., Takahata K., Konishi Y., Gallyas F., Tabira T., Sasaki R. Functionally erythropoietin receptor of the cells with neural characteristics: comparison with receptor properties of erythroid cells. J. Biol. Chem. 1993, 268:11208-11216.
24. Hanazono Y., Sasaki K., Nitta H., Yazaki Y., Hirai H. Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF receptor. Biochem. Biophys. Res. Commun. 1995, 208:1060-1066.
25. Jubinsky P.T., Krijanovski O.I., Nathan D.G., Tavernier J., Sieff C.A. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood 1997, 90:1867-1873.
26. Sánchez P., Navarro F., Fares R., Nadam J., Georges B., Moulin C., Cavorsin M., Bonnet C., Ryvlin P., Belmenguenai A., Bodennec J., Morales A., Bezin L. Erythropoietin receptor expression is concordant with erythropoietin but not with common β chain expression in the rat brain throughout the life span. J. Comp. Neurol. 2009, 514:403-414.
27. Walrafen P., Verdier F., Kadri Z., Chrètien S., Lacombe C., Mayeux P. Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 2005, 105:600-608.
28. Murphy J.M., Young I.G. IL-3, IL-5, and GM-CSF signaling: crystal structure of the human beta-common receptor. Vitam. Horm. 2006, 74:1-30.
29. Chrétien S., Varlet P., Verdier F., Gobert S., Cartron J.-P., Gisselbrecht S., Mayeux P., Lacombe C. Erythropoietin-induced erythroid differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation. EMBO J. 1996, 15:4174-4181.
30. Nakamura Y., Komatsu N., Nakauchi H. A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells. Science 1992, 257:1138-1141.
31. Arcasoy M.O., Jiang X., Haroon Z.A. Expression of erythropoietin receptor splice variants in human cancer. Biochem. Biophys. Res. Commun. 2003, 307:999-1007.
32. Maiese K., Chong Z., Shang Y. Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. Progr. Neurobiol. 2008, 85:194-213.
33. Chong Z.Z., Maiese K. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein, and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br. J. Pharmacol. 2007, 150:839-850.
34. Ramirez R., Carracedo J., Nogueras S., Buendia P., Merino A., Cañadillas S., Rodríguez M., Tetta C., Martin-Malo A., Aljama P. Carbamylated darbepoetin derivative prevents endothelial progenitor cell damage with no effect on angiogenesis. J. Mol. Cell. Cardiol. 2009, 47:781-788.
35. Xu X., Cao Z., Cao B., Li J., Guo L., Que L., Ha L., Chen Q., Li C., Li Y. Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Surgery 2009, 146:506-514.